Seventh Framework Programme and European Commission logos

Advancing the development of life-saving drugs for cardiovascular diseases

Helmholtz Zentrum München

Germany

Helmholtz Zentrum München (HMGU) will lead WP1 (Target identification), and it will construct and update a database of existing and emerging CVD-related genetic markers, as well as provide human cohort molecular data including genotyping, epigenetic and metabolomic data. In addition, HMGU will contribute to statistical and bioinformatical analyses of omics-data and to the identification and confirmation of candidate drug targets.

Helmholtz Zentrum München (HMGU) is a research institution within the Helmholtz Association of German Research Centers with approximately 2,200 associates in 40 institutes and independent research units. As one of Europe’s leading research centers, which has been awarded 11 grants from the European Research Council, it investigates chronic and complex diseases at the interface of health and environment. HMGU is aiming to promote the application of future medicine and to develop new, personalized approaches of prevention, diagnosis and therapy. HMGU has established the population-based human KORA cohort. Three institutes from the HMGU with diverse expertise are participating in this CarTarDis consortium.